Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $6.3 million.

  • Crinetics Pharmaceuticals' Receivables - Other rose 8796.32% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 8796.32%. This contributed to the annual value of $8.3 million for FY2024, which is 17236.97% up from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Receivables - Other is $6.3 million, which was up 8796.32% from $8.4 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Receivables - Other's 5-year high stood at $8.4 million during Q2 2025, with a 5-year trough of $85000.0 in Q1 2021.
  • Its 5-year average for Receivables - Other is $2.8 million, with a median of $1.4 million in 2022.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Receivables - Other crashed by 3884.89% in 2021 and then skyrocketed by 152906.98% in 2022.
  • Crinetics Pharmaceuticals' Receivables - Other (Quarter) stood at $553000.0 in 2021, then soared by 144.67% to $1.4 million in 2022, then soared by 125.5% to $3.1 million in 2023, then surged by 172.37% to $8.3 million in 2024, then dropped by 23.71% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, $8.4 million for Q2 2025, and $7.2 million during Q1 2025.